1. Home
  2. FLOC vs ABUS Comparison

FLOC vs ABUS Comparison

Compare FLOC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flowco Holdings Inc.

FLOC

Flowco Holdings Inc.

HOLD

Current Price

$24.82

Market Cap

944.8M

Sector

Industrials

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.41

Market Cap

929.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLOC
ABUS
Founded
1996
2005
Country
United States
United States
Employees
1281
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
944.8M
929.6M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
FLOC
ABUS
Price
$24.82
$4.41
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$28.50
$5.00
AVG Volume (30 Days)
629.1K
2.0M
Earning Date
05-06-2026
05-14-2026
Dividend Yield
1.31%
N/A
EPS Growth
N/A
55.26
EPS
N/A
N/A
Revenue
N/A
$14,083,000.00
Revenue This Year
$22.92
N/A
Revenue Next Year
$8.59
$239.71
P/E Ratio
$16.57
N/A
Revenue Growth
N/A
128.21
52 Week Low
$14.03
$3.04
52 Week High
$25.30
$5.10

Technical Indicators

Market Signals
Indicator
FLOC
ABUS
Relative Strength Index (RSI) 62.85 52.68
Support Level $15.04 $4.42
Resistance Level N/A $4.64
Average True Range (ATR) 0.94 0.20
MACD 0.18 -0.01
Stochastic Oscillator 84.43 56.76

Price Performance

Historical Comparison
FLOC
ABUS

About FLOC Flowco Holdings Inc.

Flowco Holdings Inc is a provider of production optimization, artificial lift, emissions management, and monetization solutions for the oil and natural gas industry. Its technologies include high-pressure gas lift (HPGL), conventional gas lift, plunger lift, and vapor recovery unit (VRU) solutions. The company operates in two reportable segments: Production Solutions, which includes rental services, and Natural Gas Technologies, which include service, gas compression parts, and equipment sales. Production Solutions: relates to rentals, sales, and services related to high-pressure gas lift, conventional gas lift, and plunger lift; including other digital solutions and methane abatement technologies, and has maximum revenue. It generates maximum revenue from the United States.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: